An advisory committee of the US Food and Drug Administration has recommended that the multiple sclerosis drug, fingolimod, be approved, according to Novartis, the drug’s manufacturer. The drug is an oral therapy that has a novel mode of action. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy